Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01892709 · ClinicalTrials.gov registry record · Phase 4
Titration of Intravenous Hydromorphone
A Phase 4 study of Acute Severe Pain, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 215
- Enrollment target
- 1
- Study location
NCT01892709 is a Phase 4 study of Acute Severe Pain that has completed, run by Montefiore Medical Center. The registered enrollment target is 215 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01892709, a Phase 4 study of Acute Severe Pain, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 215 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an exploratory, hypothesis-generating safety and efficacy study for patients who come to the ER in acute (less than 7 days in duration) severe pain. Patients with chronic pain will not be enrolled. Eligible patients will receive up to a maximum of 4 mg IV hydromorphone over a 4 hour period. Hydromorphone will be given as 1 mg increments based on how the patient responds to the question, "Do you want more pain medicine?". This question will be asked repeatedly 30 minutes after the patient answers "no" or 30 minutes after the most recent dose of IV hydromorphone (which occurs if the patient answers "yes"). Up to 10% (approximately 30 patients) will serve as a pilot at the start of the study.
Conditions Studied
Interventions
- DRUG Hydromorphone
Study Locations (1)
New York
- Montefiore Medical Center Moses Emegency Department - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01892709
The ClinicalTrials.gov registry entry for NCT01892709 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Severe Pain appearing as the primary indexed condition, and to 1 intervention - of which Hydromorphone is the first listed.
NCT01892709 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01892709 about?
NCT01892709 is a clinical study titled "Titration of Intravenous Hydromorphone". This is an exploratory, hypothesis-generating safety and efficacy study for patients who come to the ER in acute (less than 7 days in duration) severe pain. Patients with chronic pain will not be enrolled. Eligible patients will receive up to a maximum of 4 mg IV hydromorphone over a 4 hour period. ...
What is the current status of trial NCT01892709?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 215 participants. The study started on 2013-06. Estimated completion is 2014-04.
What conditions does trial NCT01892709 study?
This clinical trial studies the following conditions: Acute Severe Pain.
What interventions are being tested in trial NCT01892709?
The interventions under investigation include: Hydromorphone (DRUG).
Who is sponsoring clinical trial NCT01892709?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01892709 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.